Absci: Creating Drugs at the Speed of AI скачать в хорошем качестве

Absci: Creating Drugs at the Speed of AI

Absci is creating drugs at the speed of AI. Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Most drug discovery approaches today look to existing antibody libraries for incremental improvements; however, Absci designs antibodies "from scratch" on a computer, generating candidates unlike those found in existing databases. Their wet lab can then experimentally validate the candidates that work right out of the computer, potentially reducing the time it takes to get new drug leads into the clinic while unlocking treatments for traditionally "undruggable" diseases and improved therapeutic possibilities for many others. In this interview with Yolande Lougheed, CEO Sean McClain discusses Absci’s collaboration with leading researchers at the California Institute of Technology (Caltech) in a joint effort to discover affordable HIV therapeutic vaccinations, with the goal of making a significant step forward in the fight against the global HIV/AIDS epidemic. 0:07 Introduction 0:18 Overview of Absci 3:09 Partnership with Leading Academic Researcher, Caltech 5:19 Successful Research Collaboration with Merck https://www.absci.com | https://www.dealgateway.com Disclosure & Disclaimer International Deal Gateway (“IDG”) has been paid by Absci Corp. (“Absci”) to provide various marketing and awareness services including posting content and conducting interviews on or through our platform and e-mail subscriber list. We do not own any securities of Absci. You should not make any investment decisions based on our communications.